COMBINED TREATMENT OF HEMATOLOGICAL ONCOLOGICAL DISEASES

摘要

The invention relates to the combined treatment of hematological oncological diseases. More specifically, the combination of a telomerase inhibitor and a Bcl-2 inhibitor is useful in the treatment of hematologic oncological diseases, including AML. In some embodiments, the telomerase inhibitor is imelstat or sodium imelstat, and the Bcl-2 inhibitor is ABT-199.